Table 5.
Occurrence of AFF During or After the Use of Denosumab
| Osteoporosis (n = 11) | Bone Metastases (n = 11) | Overall (n = 22) | |
|---|---|---|---|
| Number of AFFs | 15 | 16 | 31 |
| Mean age (min-max; years) | 70.7 (59–81) | 54.7 (50–86) | 62.7 (50–86) |
| Female (%) | 10 (91%) | 10 (91%) | 20 (91%) |
| Complete AFFs (%) | 11 (73%) | 6 (38%) | 17 (77%) |
| Incomplete AFFs (%) | 4 (27%) | 10 (62%) | 14 (64%) |
| BP use | 7 (64%) | 7 (64%) | 14 (64%) |
| BP-naïve | 4 (36%) | 4 (36%) | 8 (36%) |
| Mean duration of BP, years (range) | 9.0 (5 wks–15 yrs) | 7.8 (6–11.3) | 8.4 (5 wks—15 yrs) |
| Number of denosumab doses, mean (range) | 3.2 of 60 mg half-yearly (1–14) | 30 of 120 mg monthly (18–48) | - |
| Accumulative dose, mg/year | 120 | 1440 | - |
| Number of denosumab doses in BP-naïve patients, mean (range) | 5.8 (1–14) | 29 (21–42) | - |
Abbreviations: AFF, atypical femur fracture; BP, bisphosphonate.
Parameters are based on the time of the first AFF. Mean duration of bisphosphonates was calculated in bisphosphonate users only. Incomplete fractures with progression to complete fractures were excluded from the number of incomplete AFFs. Denosumab was dosed 120 mg monthly in oncological patients and 60 mg every 6 months in osteoporosis patients. Missing data: age (n = 2) (63), mean duration of bisphosphonates (n = 3) (55), median number of denosumab doses (n = 3) (55). Included articles: (8, 42, 54–68)